Effect of triptorelin on lower urinary tract symptoms in Australian prostate cancer patients
Authors Woo HH, Murphy DG, Testa GM, Grummet JP, Chong M, Stork AP
Received 26 October 2016
Accepted for publication 17 January 2017
Published 23 February 2017 Volume 2017:9 Pages 27—35
Checked for plagiarism Yes
Review by Single-blind
Peer reviewers approved by Dr Colin Mak
Peer reviewer comments 2
Editor who approved publication: Dr Jan Colli
Henry H Woo,1 Declan G Murphy,2,3 Gerard M Testa,4 Jeremy P Grummet,5 Michael Chong,6 Andrew P Stork7
1Sydney Adventist Hospital Clinical School, University of Sydney, Wahroonga, NSW, 2Division of Cancer Surgery, Peter MacCallum Cancer Centre, Melbourne, VIC, 3Australian Prostate Cancer Research Centre, Epworth Healthcare, Richmond, VIC, 4Shire Urology, Miranda, NSW, 5Australian Urology Associates, Malvern, VIC, 6Department of Urology, Repatriation General Hospital, Daw Park, SA, 7Ipsen Pty Ltd, Glen Waverley, VIC, Australia
Purpose: Prostate cancer is often comorbidly associated with lower urinary tract symptoms (LUTS), but few studies have assessed the effects of androgen deprivation therapy on LUTS in this patient group.
Patients and methods: We conducted a prospective, noninterventional, multicenter, observational study to assess the effectiveness of triptorelin (11.25 mg every 12 weeks) over 48 weeks in men presenting with local stage T3/4 prostate cancer and moderate to severe LUTS (International Prostate Symptom Score [IPSS] >7) in a routine practice setting in Australia.
Results: Of the 44 men who enrolled, effectiveness data were available for 39 men. By the end of the study, 30% of men no longer met the IPSS criteria for moderate to severe LUTS. The proportion of patients with moderate to severe LUTS was 69.6% (16/23) at week 48 and 76.9% (30/39) at the last available visit (coprimary outcomes). An IPSS reduction of ≥3 from week 0 was observed in 47% of men at week 4, 56% at week 24, 61% (14/23) at week 48, and 61.5% (24/39) at the last available visit. Quality of life was rated as mostly satisfied-to-delighted by 39.5% of patients at week 0, 53.9% at week 24, and 77.3% at week 48. Triptorelin was well tolerated with 8 treatment-related adverse events reported, half of which were hot flushes; 5 patients discontinued due to the reported treatment-related adverse events.
Conclusion: This observational study suggests that triptorelin improves moderate to severe LUTS in prostate cancer patients in a routine clinical practice setting.
Keywords: GnRH agonist, IPSS